Last reviewed · How we verify
standard glucocorticoid therapy
Glucocorticoids reduce inflammation and suppress the immune system by binding to glucocorticoid receptors.
Glucocorticoids reduce inflammation and suppress the immune system by binding to glucocorticoid receptors. Used for Severe allergic reactions, Autoimmune disorders such as rheumatoid arthritis and lupus.
At a glance
| Generic name | standard glucocorticoid therapy |
|---|---|
| Also known as | hydrocortisone, prednisone, prednisolone, dexamethasone |
| Sponsor | Neurocrine UK Limited |
| Drug class | glucocorticoid |
| Target | glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Upon binding to glucocorticoid receptors, these drugs modulate gene expression, leading to decreased production of inflammatory cytokines and other mediators of inflammation and immune response.
Approved indications
- Severe allergic reactions
- Autoimmune disorders such as rheumatoid arthritis and lupus
Common side effects
- Cushing's syndrome
- Osteoporosis
- Hypertension
Key clinical trials
- A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Twice Weekly Steroids and Exercise as Therapy for DMD (PHASE2)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- A Study With Imlifidase in Anti-GBM Disease (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis (PHASE2)
- Taper Or Abrupt Steroid Stop: TOASSTtrial (PHASE4)
- Myositis Interstitial Lung Disease Nintedanib Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard glucocorticoid therapy CI brief — competitive landscape report
- standard glucocorticoid therapy updates RSS · CI watch RSS
- Neurocrine UK Limited portfolio CI